S5 Ep4: Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.